Kyprolis®
(carfilzomib) for injection

What is Kyprolis?

Kyprolis® (carfilzomib) for injection is a next-generation proteasome inhibitor.

What are the indications for treatment?

Kyprolis is FDA-approved for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies, including bortezomib and an immunomodulatory drug (IMiD®), and have demonstrated disease progression on or within 60 days of completion of the last therapy.

How is Kyprolis given?

Kyprolis is given as an intravenous (IV) infusion at a doctor's office, hospital, or clinic.

How often is Kyprolis given?

- Kyprolis is given in 4-week cycles.
- In each cycle, Kyprolis is given on days 1 and 2, 8 and 9, and 15 and 16. Days 17–28 are rest days with no Kyprolis given.

What is the correct dosing of Kyprolis?

- Kyprolis is given at 20 mg per square meter of body mass (20 mg/m^2) for the first cycle, and 27 mg/m^2 for all subsequent cycles, if 20 mg/m^2 is well tolerated.
- Kyprolis is given as a 2- to 10-minute IV infusion, but your doctor may choose to give it to you more slowly.
- Hydration (250–500 ml IV normal saline) is recommended with each dose of Kyprolis. There must be caution about fluid overload.

The IMF InfoLine is staffed by trained information specialists.

800.452.CURE (2873) *in the US & Canada*

International Myeloma Foundation

12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA
818.487.7455 myeloma.org

How long will treatment be given?

- Treatment with Kyprolis will continue as long as it is working and side effects are tolerable.
- Kyprolis can be dose-reduced or stopped until the side effect improves, and then resumed again.

What are the most common side effects?

- Fatigue, low red cell count (anemia), nausea, low platelet count (thrombocytopenia), shortness of breath, diarrhea, and fever.
- Dizziness, fainting, or a drop in blood pressure. Do not drive or operate machinery if you experience these symptoms.

Are there other serious side effects of Kyprolis to be aware of?

- Cardiac issues including heart failure have been reported in patients receiving Kyprolis (7% of 526 trial patients).
- Although underlying heart disease does not exclude use of Kyprolis, NYHA Class III and IV patients were and are excluded from clinical trials.
- Shortness of breath (dyspnea) can occur with Kyprolis, and was reported in ~35% of trial patients.
- If anything suggestive of heart or lung difficulties bothers you and does not go away, call your doctor and/or seek medical attention.

Does my health insurance cover Kyprolis treatment?

For questions about insurance coverage or financial assistance for uninsured patients, call ONYX 360 at 855-ONYX-360.

As always, the IMF urges you to discuss all medical issues with your doctor, and to contact the IMF for information about myeloma.

International **Myeloma** Foundation

Improving Lives **Finding the Cure**®

tc-kypro_d1_2015